10/3/2012 10:23:27 AM
NOKOMIS, Fla.--(BUSINESS WIRE)--In a continuing effort to expand its research into possible cures for neurological diseases gaining in prevalence, Rainbow Coral Corp.’s (OTCBB: RBCC) biotech subsidiary, Rainbow Biosciences, is looking to China for possible partners for stem cell research. Last month, RBCC announced that it was in talks to acquire a license to use a NASA-developed bioreactor to multiply adult stem cells for research. As RBCC closes in on an agreement with the cutting-edge device’s license holders, Amarantus BioSciences (OTCBB: AMBS), China has emerged as a logical location to set up shop conducting medical research using the powerful tool.
comments powered by